A recent engadget article noted the first human Ebola vaccine to receive EU approval. Merck’s ERVEBO is the product of a unique collaboration between the Public Health Agency of Canada and the US Army over ten years ago. Merck acquired the rights to develop the vaccine after the 2014 Ebola outbreak in West Africa. On November 11th, the vaccine received a “conditional marketing authorization,” a distinction typically designated for medicines that treat unmet medical needs.
Quick Hits: EU Approves Human Ebola Vaccine
In a new first, Merck’s Ebola vaccine received a “conditional marketing authorization” from the European Union.
Nov 20, 2019
Fill out the form below to request more information about Quick Hits: EU Approves Human Ebola Vaccine
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
Read More
